Clinical Trials Logo

Corneal Neovascularization clinical trials

View clinical trials related to Corneal Neovascularization.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT01996826 Completed - Clinical trials for Corneal Neovascularization

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Start date: April 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe and effective at decreasing the likelihood of a high-risk corneal graft rejection. Patients who are "high-risk" for rejection have blood vessels growing from the white of the eye into the cornea (clear, front region of the eye). The medication is used at the time of surgery and in the weeks following surgery. Participants have a 50/50 chance at receiving the active study medication or a placebo medication.

NCT ID: NCT01843101 Completed - Keratoconus Clinical Trials

Investigation of Different Scanning Protocols for 3 Dimensional High-resolution Imaging of the Human Cornea With Optical Coherence Tomography (OCT) - A Pilot Study

Start date: March 14, 2014
Phase: Phase 2
Study type: Interventional

The aim of the present study is to develop a protocol for optimal corneal 3-dimensional imaging based on measurements in healthy volunteers. For this purpose, a customized ultra-high resolution Spectral Domain OCT will be used. To validate whether the protocol can also be applied in patients with corneal pathologies, for whom it is intended to be used, measurements in these patients will be performed. We propose to obtain images from patients with keratoconus, since this is one of the most frequent causes for corneal transplantations in Europe and from patients with corneal neovascularization which is a major cause of vision loss in several ophthalmic diseases. Based on the obtained measurement protocol, further studies investigating the pathophysiology or treatment success of several corneal pathologies can be planned.

NCT ID: NCT01257750 Completed - Clinical trials for Corneal Neovascularization

Treatment of Corneal Neovascularization With Topical Pazopanib

Start date: November 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of a drug [Pazopanib (Votrient)] as a treatment for corneal neovascularization. The cornea is the clear, central portion of the eye and neovascularization means blood vessel growth. The cornea is typically avascular, or without blood vessels. Corneal neovascularization in the cornea and can put vision at risk. Numerous diseases of the cornea such as inflammation, ischemia (restriction of blood supply), infection, degeneration (or deterioration), trauma, or corneal stem cell deficiency can lead to corneal neovascularization. This major ocular complication can lead to corneal scarring, edema (swelling), lipid deposits, and inflammation that may significantly alter your vision. In addition, it worsens the outcome of potential future treatments, such as a corneal transplant. A corneal transplant is a treatment that many patients with severe corneal disease may ultimately need.

NCT ID: NCT01072357 Completed - Clinical trials for Corneal Neovascularization

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Start date: December 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The leading risk factor for corneal transplant rejection is abnormal blood vessel growth of the host bed. Vascular endothelial growth factor (VEGF) is thought to be a mediator of this corneal neovascularization (NV), therefore we would like to test the safety and efficacy of local VEGF blockade in the promotion of graft survival in high risk corneal transplants.

NCT ID: NCT00797303 Completed - Clinical trials for Corneal Neovascularization

The Effect of Bevacizumab on Corneal Neovascularization

BQ-1-08-ARVO
Start date: January 2006
Phase: Phase 4
Study type: Interventional

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

NCT ID: NCT00769145 Completed - Clinical trials for Corneal Neovascularization

Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Start date: October 2008
Phase: Phase 1
Study type: Interventional

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.

NCT ID: NCT00681889 Completed - Clinical trials for Corneal Neovascularization

Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)

Start date: April 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.

NCT ID: NCT00559936 Completed - Clinical trials for Corneal Neovascularization

Topical Avastin for Treatment of Corneal Neovascularization

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.

NCT ID: NCT00555594 Completed - Clinical trials for Corneal Neovascularization

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Start date: September 2006
Phase: Phase 2/Phase 3
Study type: Interventional

To determine the effect of subconjunctival Bevacizumab in corneal neovascularization

NCT ID: NCT00512876 Completed - Clinical trials for Corneal Neovascularization

Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

Start date: August 2007
Phase: N/A
Study type: Interventional

Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.